AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30946021 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartHab app
Number of subjects: 32
Study 30946022 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach-facilitated digital cognitive behavioral program
Number of subjects: 593
Study 30946022 — intervention group
Group type: COMPARATOR
Intervention: Control group (CAU)
Number of subjects: 593
Study 30946162 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected smokers
Number of subjects: 330
Study 30946162 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected smokers
Number of subjects: 330
Study 30946294 — intervention group
Group type: EXPERIMENTAL
Intervention: Current practices involving consultation of multiple rehabilitation services for each case example provided.
Number of subjects: 148
Study 30946294 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in developing and implementing guidelines for PICU-based rehabilitation.
Number of subjects: 148
Study 30946294 — intervention group
Group type: EXPERIMENTAL
Intervention: Need for additional research evidence.
Number of subjects: 148
Study 30946294 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to implementation of PICU-based rehabilitation.
Number of subjects: 148
Study 30946294 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of long-term functional outcomes of PICU patients.
Number of subjects: 148
Study 30946553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir (4 weeks post-transplant)
Number of subjects: 44
Study 30946553 — intervention group
Group type: COMPARATOR
Intervention: HCV-infected lung-transplant recipients
Number of subjects: 44
Study 30946917 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborn SCID screening using quantification of T-cell receptor excision circles (TRECs) on Guthrie cards
Number of subjects: 190517
Study 30946917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SCID screening)
Number of subjects: 190517
Study 30946917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost of screening
Number of subjects: 190517
Study 30946917 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 190517
Study 30946996 — intervention group
Group type: EXPERIMENTAL
Intervention: Permacol™ intervention for CAWHR repair
Number of subjects: 77
Study 30947300 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for DCM
Number of subjects: 757
Study 30947753 — intervention group
Group type: EXPERIMENTAL
Intervention: SOFA score
Number of subjects: 1532
Study 30947753 — intervention group
Group type: EXPERIMENTAL
Intervention: IDSA/ATS minor criteria
Number of subjects: 1532
Study 30947753 — intervention group
Group type: EXPERIMENTAL
Intervention: SCAP
Number of subjects: 1532
Study 30947753 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, sex, and pack-years
Number of subjects: 1532
Study 30947753 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiosis before hospitalization
Number of subjects: 1532
Study 30947942 — intervention group
Group type: EXPERIMENTAL
Intervention: CENTERA transcatheter heart valve (THV)
Number of subjects: 203
Study 30948185 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon pulmonary vein isolation (CB-PVI)
Number of subjects: 460
Study 30948361 — intervention group
Group type: EXPERIMENTAL
Intervention: High socioeconomic status (SES)
Number of subjects: 1259
Study 30948361 — intervention group
Group type: COMPARATOR
Intervention: Low socioeconomic status (SES)
Number of subjects: 1259
Study 30948562 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics model for prediction of adverse motor outcomes
Number of subjects: 394
Study 30948562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant and Toddler Development-III (Bayley-III)
Number of subjects: 394
Study 30948562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley-III and Gross Motor Function Classification System
Number of subjects: 394
Study 30948562 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-modelling methodology
Number of subjects: 394
Study 30948594 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary lactate measured by CL-Scout+
Number of subjects: 240
Study 30948594 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary lactate measured by CL-Nova
Number of subjects: 240
Study 30948594 — intervention group
Group type: COMPARATOR
Intervention: Venous lactate measured by VL-Scout+
Number of subjects: 240
Study 30948594 — intervention group
Group type: COMPARATOR
Intervention: Venous lactate measured by VL-Nova
Number of subjects: 240
Study 30948618 — intervention group
Group type: EXPERIMENTAL
Intervention: Colli-Pee device for home urine collection
Number of subjects: 213
Study 30948618 — intervention group
Group type: COMPARATOR
Intervention: Routine clinic-based urine collection
Number of subjects: 213
Study 30949218 — intervention group
Group type: EXPERIMENTAL
Intervention: Shensong Yangxin (SSYX)
Number of subjects: 333
Study 30949218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333
Study 30949435 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided internet-delivered individually-tailored ACT-influenced cognitive behavioural intervention (iNNOVBC) for 10 weeks
Number of subjects: 0
Study 30949435 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) in a waiting list control group (WLC)
Number of subjects: 0
Study 30949667 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverages (each extra serving per day)
Number of subjects: 1966
Study 30949667 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk (replacement of 5 En% of alcoholic beverages)
Number of subjects: 1966
Study 30949667 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverages (replacement of 5 En% of alcoholic beverages)
Number of subjects: 1966
Study 30949674 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals treatment
Number of subjects: 242
Study 30949674 — intervention group
Group type: EXPERIMENTAL
Intervention: Registry follow-up
Number of subjects: 242
Study 30949674 — intervention group
Group type: COMPARATOR
Intervention: Cirrhosis status
Number of subjects: 242
Study 30949906 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime faster aspart with carbohydrate counting
Number of subjects: 2168
Study 30949906 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp)
Number of subjects: 2168
Study 30949906 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (mealtime faster aspart and IAsp)
Number of subjects: 2168
Study 30949907 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 12
Study 30949907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30950636 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone treatment, timing of treatment initiation not specified.
Number of subjects: 0
Study 30950802 — intervention group
Group type: EXPERIMENTAL
Intervention: Web version of the intervention (HŞKA)
Number of subjects: 444
Study 30950802 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app of the intervention with automated supportive SMS based on PST
Number of subjects: 444
Study 30950802 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (access to intervention after 4 months)
Number of subjects: 444
Study 30951600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus an optimized background regimen
Number of subjects: 23
Study 30951840 — intervention group
Group type: EXPERIMENTAL
Intervention: One-time infusion of donor-derived cytokine-induced killer (CIK) cells at a dose of 1 × 10^6 cells/kg.
Number of subjects: 0
Study 30951840 — intervention group
Group type: COMPARATOR
Intervention: Non-myeloablative conditioning with total lymphoid irradiation and antithymocyte globulin (TLI-ATG).
Number of subjects: 0
Study 30952488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea 20 mg/kg/day
Number of subjects: 29
Study 30952488 — intervention group
Group type: COMPARATOR
Intervention: Standard care protocol
Number of subjects: 29
Study 30952529 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy (LVH) identified by LV mass index >46.7 g/m
Number of subjects: 132
Study 30952529 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of LVH
Number of subjects: 132
Study 30952529 — intervention group
Group type: EXPERIMENTAL
Intervention: LVH
Number of subjects: 132
Study 30952559 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated quantitative analysis of MRI using artificial neural networks (ANN)
Number of subjects: 455
Study 30952619 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (87% of patients)
Number of subjects: 419
Study 30952619 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of PIK3CA alterations (40%)
Number of subjects: 419
Study 30952619 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of KMT2D (15%) and KMT2C (16%) alterations
Number of subjects: 419
Study 30952619 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-of-function mutations in epigenetic modulator genes (47%)
Number of subjects: 419
Study 30952619 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR4 gene amplifications (10%)
Number of subjects: 419
Study 30952619 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor (AR) gene alterations (7%)
Number of subjects: 419
Study 30952619 — intervention group
Group type: EXPERIMENTAL
Intervention: RPPA protein expression analysis
Number of subjects: 419
Study 30952640 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone (KDD)
Number of subjects: 23
Study 30952998 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimentin over-expressing cells
Number of subjects: 192
Study 30952998 — intervention group
Group type: COMPARATOR
Intervention: Vimentin lacking cells
Number of subjects: 192
Study 30952998 — intervention group
Group type: COMPARATOR
Intervention: Serum Vimentin levels in patients with sepsis
Number of subjects: 192
Study 30952998 — intervention group
Group type: COMPARATOR
Intervention: Vimentin expression in lymphocytes from septic patients
Number of subjects: 192
Study 30952998 — intervention group
Group type: COMPARATOR
Intervention: Serum Vimentin levels in nonsurvivor group
Number of subjects: 192
Study 30953061 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal challenge with influenza A(H1N1)pdm09 virus
Number of subjects: 7
Study 30953148 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary equol (measured by high-performance liquid chromatography-tandem mass spectrometry)
Number of subjects: 2818
Study 30953148 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary equol (men)
Number of subjects: 2818
Study 30953148 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary equol (women)
Number of subjects: 2818
Study 30953148 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary equol (third tertile)
Number of subjects: 2818
Study 30953148 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP and RBP4
Number of subjects: 2818
Study 30953238 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (20, 30, 40, or 50 mg/day; physician decision)
Number of subjects: 1602
Study 30953533 — intervention group
Group type: EXPERIMENTAL
Intervention: RPV-based regimen after switching from NNRTI or boosted PI
Number of subjects: 320
Study 30953533 — intervention group
Group type: EXPERIMENTAL
Intervention: RPV-based regimen
Number of subjects: 320
Study 30953560 — intervention group
Group type: COMPARATOR
Intervention: Methylated INS cfDNA
Number of subjects: 40
Study 30953560 — intervention group
Group type: COMPARATOR
Intervention: Unmethylated INS cfDNA
Number of subjects: 40
Study 30953560 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylated and unmethylated INS cfDNA pooled
Number of subjects: 40
Study 30953560 — intervention group
Group type: COMPARATOR
Intervention: Clinical measurements of β-cell function and pre-diabetes
Number of subjects: 40
Study 30954166 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacterial lyophilizates
Number of subjects: 0
Study 30954166 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-immunoglobulin E
Number of subjects: 0
Study 30954352 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with mitomycinC/doxorubicin for 90 min
Number of subjects: 140
Study 30954352 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin for 90 min
Number of subjects: 140
Study 30954352 — intervention group
Group type: COMPARATOR
Intervention: HIPEC with oxaliplatin for 30 min
Number of subjects: 140
Study 30954352 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with 90 min (mitomycinC/doxorubicin or cisplatin)
Number of subjects: 140
Study 30954510 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 350
Study 30954510 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin
Number of subjects: 350
Study 30954640 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 0
Study 30954643 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0
Study 30954717 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (chemotherapy with ifosfamide/doxorubicin)
Number of subjects: 63
Study 30954717 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery ± radiotherapy for low-risk patients
Number of subjects: 63
Study 30954717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate-/high-risk therapy (chemotherapy ± surgery ± radiotherapy)
Number of subjects: 63
Study 30954717 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of event-free survival
Number of subjects: 63
Study 30954717 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients
Number of subjects: 63
Study 30955188 — intervention group
Group type: EXPERIMENTAL
Intervention: Evocalcet 1-8 mg orally once daily for 32 weeks
Number of subjects: 39
Study 30955357 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 16443
Study 30955357 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 16443
Study 30955420 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg cannabidiol
Number of subjects: 225
Study 30955420 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg cannabidiol
Number of subjects: 225
Study 30955420 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 30955983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet (lacto-ovo vegetarians and vegans)
Number of subjects: 13935
Study 30955983 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet
Number of subjects: 13935
Study 30955983 — intervention group
Group type: COMPARATOR
Intervention: Nonvegetarian diet
Number of subjects: 13935
Study 30956579 — intervention group
Group type: EXPERIMENTAL
Intervention: ISO-Gard
Number of subjects: 0
Study 30956800 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone application for daily breathlessness rating (0-10 NRS)
Number of subjects: 0
Study 30956800 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily and weekly recall of breathlessness
Number of subjects: 0
Study 30956961 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum arabic (GA) 30 g/day for 12 weeks
Number of subjects: 47
Study 30957229 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction chemotherapy plus bortezomib
Number of subjects: 135
Study 30957420 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive safer conception package including ART for HIV-positive partners, PrEP for HIV-negative partners, SMS surveys for tracking, counselling on self-insemination, referrals for circumcision and fertility care.
Number of subjects: 74
Study 30957581 — intervention group
Group type: EXPERIMENTAL
Intervention: PEGylated non-biologic drugs
Number of subjects: 0
Study 30958020 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavior therapy (ICBT) course (8-week guided)
Number of subjects: 8
Study 30958033 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30958102 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic navigation bronchoscopy (ENB) for fiducial marker placement
Number of subjects: 258
Study 30958884 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BDI-II scores
Number of subjects: 125
Study 30958884 — intervention group
Group type: EXPERIMENTAL
Intervention: 2MST (2 min step test)
Number of subjects: 125
Study 30958892 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg orally once daily (QD) 3 weeks on/1 week off combined with intravenous cetuximab 250 mg/m²
Number of subjects: 0
Study 30958892 — intervention group
Group type: EXPERIMENTAL
Intervention: Various dose levels of regorafenib administered QD continuously or intermittently (3 weeks on/1 week off)
Number of subjects: 0
Study 30959003 — intervention group
Group type: EXPERIMENTAL
Intervention: NPR with leakage
Number of subjects: 40
Study 30959003 — intervention group
Group type: EXPERIMENTAL
Intervention: NPR without leakage
Number of subjects: 40
Study 30959003 — intervention group
Group type: EXPERIMENTAL
Intervention: NPR with leakage in the posterior region
Number of subjects: 40
Study 30959003 — intervention group
Group type: EXPERIMENTAL
Intervention: NPR without leakage in the mid-periphery
Number of subjects: 40
Study 30959163 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (9 doses, i.v., 1 dose every 21 days starting on day +14 post-AHCT)
Number of subjects: 32
Study 30959477 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (2800 IE daily)
Number of subjects: 108
Study 30959477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 30961941 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD Assessment Test (CAT)
Number of subjects: 3452
Study 30961941 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple linear regression analysis
Number of subjects: 3452
Study 30961941 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT and mMRC classification
Number of subjects: 3452
Study 30961941 — intervention group
Group type: EXPERIMENTAL
Intervention: CAT >10
Number of subjects: 3452
Study 30962120 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sugar diet (added sugars comprised 2.5% to 4.0% of daily calories)
Number of subjects: 42
Study 30962222 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRPαFc (TTI-621), a novel CD47 decoy receptor, administered in clinical trial settings.
Number of subjects: 0
Study 30962222 — intervention group
Group type: EXPERIMENTAL
Intervention: CD47 expression on Sézary cells influenced by interleukin 4 (IL-4), IL-7, and IL-13.
Number of subjects: 0
Study 30962233 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatment practices for PDN according to guidelines and local practices
Number of subjects: 1500
Study 30962275 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher cortical thickness in medial prefrontal, anterior cingulate, and orbitofrontal areas associated with YoE.
Number of subjects: 122
Study 30962275 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct gene expression profile in YoE-related brain regions.
Number of subjects: 122
Study 30962275 — intervention group
Group type: EXPERIMENTAL
Intervention: Genome-wide expression profile analysis of YoE-related brain regions.
Number of subjects: 122
Study 30962330 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (single oral dose of isavuconazonium sulfate)
Number of subjects: 48
Study 30962334 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS) at 15 mg/kg every 6 hours
Number of subjects: 56
Study 30962334 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS) at 20 mg/kg every 6 hours
Number of subjects: 56
Study 30962334 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS) at 25 mg/kg every 6 hours
Number of subjects: 56
Study 30962334 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin (IMP-CS)
Number of subjects: 56
Study 30962681 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide/formoterol fumarate (AB/FF) 400/12 µg
Number of subjects: 1594
Study 30962681 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 µg
Number of subjects: 1594
Study 30962681 — intervention group
Group type: COMPARATOR
Intervention: Aclidinium (AB) 400 µg
Number of subjects: 1594
Study 30962681 — intervention group
Group type: COMPARATOR
Intervention: Formoterol (FF) 12 µg
Number of subjects: 1594
Study 30962697 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 0
Study 30962697 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 plus insulin aspart
Number of subjects: 0
Study 30962703 — intervention group
Group type: EXPERIMENTAL
Intervention: Random forest method
Number of subjects: 573
Study 30962703 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear model
Number of subjects: 573
Study 30962703 — intervention group
Group type: EXPERIMENTAL
Intervention: Support vector machine
Number of subjects: 573
Study 30962703 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision tree
Number of subjects: 573
Study 30962703 — intervention group
Group type: EXPERIMENTAL
Intervention: Feed-forward neural network
Number of subjects: 573
Study 30962703 — intervention group
Group type: COMPARATOR
Intervention: Stenting
Number of subjects: 573
Study 30962703 — intervention group
Group type: COMPARATOR
Intervention: Best medical therapy
Number of subjects: 573
Study 30962707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (150 mg/day to 600 mg/day, titrated over 1-4 weeks)
Number of subjects: 3
Study 30962707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3
Study 30962729 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (60 mg once daily)
Number of subjects: 409
Study 30962729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 409
Study 30962963 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 10 mg/m2/day
Number of subjects: 9
Study 30962963 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 15 mg/m2/day
Number of subjects: 9
Study 30962963 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion at 20 mg/m2/day
Number of subjects: 9
Study 30962963 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion
Number of subjects: 9